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Suite 475, Department of Restorat, Houston, TX 77030, USAReceived 22 October 2005; accepted 24 October 2005Summary Human papilloma virus (HPV) is the most common sexually transmitted viral disease
responsible for mucosal warts and anogenital malignancies. HPV-associated oral lesions include
condyloma, focal epithelial hyperplasia and some squamous cell carcinomas. Recent studies
have shown an increased risk of oral warts in HIV positive individuals. This article, reports an
unusual presentation of a disseminated oral HPV infection in a newly diagnosed HIV positive
patient after the initiation of highly active antiretrovirals therapy (HAART).c 2005 Elsevier Ltd. All rights reserved.
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dCase report
A 22 year old African-American male presented to the clinic
for evaluation of multiple oral lesions (Fig. 1). The patient
was recently diagnosed with HIV (four months) and was
started on the highly active antiretroviral drug therapy.
He first noticed the lesions on his lips three weeks after
starting his antiretroviral medications (Fig. 2). Intraoral
exam examination revealed multiple papillary raised lesions
measuring 0.2–0.8 cm in diameter disseminated intra-orally
on the labial and buccal mucosa (Figs. 2–6). There were
no other oral lesions, tumors or masses noted intraorally.
Review of systems was unremarkable with no otalgia,741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reserved
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E-mail addresses: orasmile@gmail.com, shettyk@yahoo.comdysphagia, odynophagia, hoarseness or coughing. The pa-
tient’s extra oral exam revealed a normocephalic facial
symmetry with no signs or symptoms of acute infection,
swelling or tenderness. The patient did not have any other
significant medical history. His CD4 count was 220 and the
viral load was 20500. The patient was presently on a regi-
men of nevirapine (Viramune; Boehringer Ingelkeim Corpo-
ration, Connecticut, USA), Ritonavir (Kaletra; Abbott
Laboratories, IL, USA), ABACAVIR (Ziagen; Glaxosmithkline,
Munich, Germany) and efavirenz (Sustiva; Bristol Myers
Squibb, Chicago, USA). There was no history of tobacco,
alcohol or illicit drug use. The patient agreed to undergo
an incisional biopsy of the lesions on two different sites in
the maxillary and mandibular region. The histologic exami-
nation revealed a benign papillary lesion consistent with a
diagnosis of papilloma from each site biopsied. The patient
was referred to the oral and maxillofacial surgery clinic for
laser ablation of the papillary lesions..
Figure 1 Initial presentation of the patient six weeks after
initiation of the antiretroviral therapy.
Figure 6 Multiply papillary lesions ranging from 0.2 to 0.6 cm
in diameter on the lower anterior and posterior mucosal
regions.
Figure 2 Multiply papillary raised lesions ranging from 0.2 to
0.8 cm in diameter on the upper and lower lip region extending
to either side of the commisure.
Figure 4 Multiply papillary lesions ranging from 0.2 to 0.6 cm
in diameter on the left posterior alveolar and buccal mucosa.
Figure 5 Multiply papillary lesions ranging from 0.2 to 0.6 cm
in diameter on the right labial mucosa extending towards the
posterior alveolar mucosa.
Figure 3 Multiply papillary lesions ranging from 0.2 to 0.8 cm
in diameter on maxillary labial and alveolar mucosa.
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HIV has indirectly claimed the lives of over three million
people to date, and over 40 million people worldwide arecurrently HIV-infected (Joint United Nations Program on
HIV/AIDS, 2002 statistics, <www.unaids.org>). HIV pre-
ferentially infects CD4+ T lymphocytes, resulting in a
progressive depletion of these cells. This leads to immuno-
deficiency and subsequent opportunistic infections, includ-
ing oral infections. Half of all HIV-infected people
experience an oral opportunistic infection within five years
of HIV seroconversion.1 These infections include oropha-
ryngeal candidiasis (‘‘oral thrush’’, OPC), oral hairy leuko-
Disseminated oral HPV lesion eruptions after the initiation of antiretroviral therapy 155plakia (OHL, caused by Epstein-Barr virus), oral Kaposi’s sar-
coma (caused by human herpesvirus-8, HHV-8) and oral con-
dylomas (caused by human papilloma virus, HPV). While
opportunistic infections of the oral cavity are usually not
life threatening, they do lead to significant morbidity and
health care costs for HIV-infected individuals.
As with the HIV population there are large differences
between the infection rates with HPV and the occurrence
of oral lesions,2–4 however, these HPV-associated lesions
occur more commonly under conditions of immune suppres-
sion.5–7 In addition, oral lesions similar to those seen in
HIV individuals contain additional or novel HPV types in a
significant subpopulation. (2.5–4% of HIV+ patients).6
Greenspan et al. have described cauliflower and spiky warts
containing HPV type 7 and flat warts, similar in appearance
to FEH, containing HPV 13, 18 and 32.8,9 A study of benign
oral lesions, not restricted to warts, Volter et al. found
HPV DNA sequences in 67% of the specimens.3 The most
common types found were HPV 32 (28%) and HPV 7 (19%),
which would have been missed if testing only for genital
HPV types. A study on oral squamous cell carcinomas in
HIV+ individuals have demonstrated an early age of onset,
an aggressive course, and a high rate of HPV DNA
detection.10
Comparative studies have shown that HPV infection is in-
creased in the HIV+ individual as demonstrated by Coutlee
et al. where HPV DNA was detected in 2.6% of the oral cav-
ities of HIV adults compared to 14.4% of the HIV+ individu-Table 1 Antiretroviral drug list
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Mechanism of action: Nucleoside analogues enter the cell and are p
active triphosphate metabolite. Nucleotides differ from nucleoside
they inhibit HIV-1 reverse transcriptase by competing with natura
process prevents chain elongation, which ultimately prevents HIV
Abacavir (ABC)
Didanosine (ddl)
Emtricitabine (FTC)
Lamivudine (3TC)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Mechanism of action: Similar to the nucleoside/nucleotide RTIs, t
They act, however, by noncompetitive inhibition, binding directly
polymerase activities.
Delavirdine (DLV)
Efavirenz (EFV)
Protease Inhibitors
Mechanism of action: These antiretroviral agents inhibit the enzy
precursors to generate functional proteins in HIV-infected cells. P
new cells, and viral replication.
Amprenavir (APV)
Atazanavir (ATV)
Fosamprenavir (FPV)
Indinavir (IDV)
Cell Fusion Inhibitors
Mechanism of action: Fusion inhibitors prevent the entry of HIV-1
membranes.
Enfuvirtide (T-20)als.11 Again, only genital types of HPV were studied and no
specific methods to detect non-genital types of HPV were
attempted, which could lead to an underestimation of the
HPV prevalence rates. Genital HPV infection is also in-
creased in HIV+ women compared to HIV women with more
women infected with multiple types of HPV, particularly
high-risk HPV infections leading to anogenital malignan-
cies.12,13 Women represent a growing percentage of the
HIV+ population and indeed the risk factors for oral HPV
infection in HIV+ women may differ from HIV+ men, as
may the rates of HPV-related oral disease. In addition, the
genital tract could serve as a reservoir for current or future
oral infection. Clearly, studies are needed to more fully
examine the site of oral HPV infection as well as the geno-
type(s) involved.
The health of HIV-infected patients relies on the long-
term control of HIV viral load and subsequent restoration
of immunity. The most successful therapeutic approach to
date has been a combination-drug approach known as highly
active antiretroviral therapy (HAART). HAART typically con-
sists of a cocktail of three drugs, two of which are nucleo-
side analogue reverse transcriptase (RT) inhibitors, and
one of which is either a non-nucleoside RT inhibitor or a pro-
tease inhibitor (PI). A new class of drug namely the Fusion
Inhibitors has been recently released as well. These drugs
have been summarized in Table 1. HAART has been respon-
sible for decreasing HIV plasma viral loads, increasing CD4+
T lymphocyte counts, prolonging the progression to AIDShosphorylated by cellular kinases that convert them to their
s because they possess a phosphate group. Once activated,
l substrates and by incorporating into the viral DNA. This
replication in infected cells.
Stavudine (d4T)
Tenofovir (TDF)
Zalitabine (ddC)
Zidovudine (ZDV or AZT)
hese antiretroviral drugs also inhibit reverse transcriptase.
to reverse transcriptase, blocking RNA- and DNA-dependent
Nevirapine (NVP)
me protease. Protease is used to cleave viral polyprotein
rotease inhibitors prevent HIV cell maturation, infection of
Lopinavir (LPV)
Nelfinavir (NFV)
Ritonavir (RTV)
Saquinavir (SQV)
into cells by inhibiting the fusion of viral and cellular
156 K. Shettyand decreasing the mortality from HIV.5 HAART has also de-
creased the incidence of opportunistic infections, including
those of the oral cavity. Since the administration of HAART
therapy, the incidences of OPC and OHL have significantly
decreased.14 In stark contrast, the reported incidence of
oral warts in HIV+ individuals has significantly increased dur-
ing the era of HAART. A report in Lancet by Greenspan et al.
demonstrated a rise in the incidence of oral warts in HIV+
patients in San Francisco in the 1990’s.14 Similarly, King
et al. reported increased incidence of oral warts in an Atlan-
ta HIV cohort.15 The reasons for the unexpected rise in inci-
dence of oral warts remain unknown; the spectrum of
possibilities includes epidemiological (e.g., an epidemic of
oral HPV infections, or unknown epidemiological con-
founder that explains the observation), chemical (e.g., a di-
rect impact of treatment regimens on host or virus), viral
(interactions between HIV and HPV and/or changes in their
ecological niches), and immunological (e.g., immune resto-
ration disease, or a lack of restoration of an essential com-
ponent of HPV immune control).
Conclusion
Human papilloma virus is a ubiquitous pathogen that infects
mucosal surfaces especially the genital tract and oral cav-
ity. The current clinical observation of an increase in oral
pathology due to HPV in the HIV+ individual in the setting
of active anti-retroviral therapy implies the lack of mucosal
immune reconstitution.
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